Content as a Compass: Using Content in Life Science ABM to Surface In-Market Buying Groups

In most B2B marketing programs, content has one job: generate traffic and leads. A white paper or blog post goes live, search and ads drive traffic to it, and for gated assets the hope is a form fill that feeds a nurture sequence. Content builds brand and captures leads, and its value is measured in visits and conversions.

In a well-constructed life science Account-Based Marketing program, content does something more useful than that. It works as a diagnostic instrument. When the right content is placed in front of the right audience, the pattern of who engages, when, and how deeply reveals whether a buying group is forming around a specific need at a target account, along with who the specific members of that buying group likely are. The content is not just attracting interest; it is surfacing intent.

That distinction changes how you plan content, how you deploy it, and what you do with the engagement data it generates. This post walks through all three of these areas.

Why Content Works Differently in Life Sciences

The scientific training that makes life science buyers skeptical of promotional messaging also makes them genuinely receptive to content that helps them do their jobs. A translational scientist working through exploratory biomarker endpoints for a Phase 1 oncology program will engage seriously with a substantive white paper on relevant assay methods, not because she is in a purchasing mindset, but because it is directly useful to her work. A clinical program director navigating the move from Phase 1 to Phase 2 will read a case study on how a peer organization managed that transition, because it offers applicable insight.

Neither of them necessarily set out to evaluate vendors. Their engagement is still a commercially meaningful signal: it suggests an active project.

This is the foundation of content-driven ABM in life sciences. The content that attracts your audience is the same content that reveals what they are working on right now. A scientist reading an application note on a specific assay methodology is telling you something about her current research context. A program director downloading a Phase 2 trial design guide is telling you something about the stage of his program. When those signals come from individuals at accounts you pre-selected for their programs in development, upcoming trials, or recent funding, they mean something that generic web traffic never will.

There is a further complication that makes this signal even more valuable. Mid-size and larger life science organizations rarely run one program at a time. For example, a biotech with three active clinical programs may have three or four clinical program directors; a large pharma will have dozens of scientists with biomarker or translational medicine in their titles. Knowing the right persona to target does not tell you which of those people is connected to the program your solution actually serves. A database search filtered by title returns a list of plausible candidates. It cannot tell you which of them belongs to the buying group.

Content closes that gap. When ads and content are built around a specific therapeutic area, modality, or development stage, the people who engage are disproportionately those working on programs that match the profile. Those who do not engage are probably attached to programs where the content is not relevant, whatever their titles say. Engagement behavior, read at the individual level, filters the list of plausible candidates down to the probable members of the buying group for the program being sold into.

But for this all to be effective in driving pipeline and ROI, content for this audience has to be genuinely useful to scientifically trained readers, substantive enough to earn engagement from people who evaluate everything with critical judgment. Promotional content dressed in scientific language will not generate the engagement patterns that reveal buying intent. Real expertise, communicated clearly and practically, will.

Building the Content Matrix

The planning tool that connects content strategy to ABM execution is the content matrix: a framework mapping content types and formats to each buying committee persona at each funnel stage. The output is a set of parallel content tracks, one per committee persona, that together create the conditions for engagement across the full group.

Top of funnel (TOFU). The goal is broad awareness and surfacing accounts with relevant interest. Content here is educational and problem-focused: blog posts on common challenges at a specific development stage, guides on regulatory or scientific topics, pre-recorded educational webinars at the intersection of your expertise and your audience's priorities. This content should be largely ungated. Its purpose is to be found, consumed, and associated with your organization's expertise, not to generate form fills. The signal it produces is traffic and repeat visitation, which from a target account is a meaningful early indicator.

Middle of funnel (MOFU). Content shifts from education to evaluation support, and this is where gated assets earn their place: white papers with original data or analysis, benchmark reports, technical problem-solving guides, and live webinars with real subject-matter depth. These formats ask for a meaningful commitment from the reader and offer enough value to justify handing over contact information. The form fill captures more than a name and email. It captures a specific declaration: this person, at this company, cares about this topic, at this depth.

Persona differentiation matters most at this stage. A biomarker strategy white paper speaks to the scientific end-user and program lead. A delivery-performance case study speaks to the program lead and procurement. A vendor qualification guide speaks to procurement and legal. Run the tracks in parallel and the engagement data you collect reflects the whole committee, not just the scientists.

Bottom of funnel (BOFU). Content now supports active evaluation: ROI and total-cost calculators, detailed capability overviews, regulatory credential documentation, reference case studies, proposal-ready summaries. Deliver it to engaged contacts without friction. The last thing you want, when a buying group is building the internal case for your solution, is a barrier between them and the information they need.

Key note: In reality it may not be possible or practical to create all content for each funnel stage and specific to each persona. However, you may have existing pieces of content relevant across multiple personas, and you may have pieces of content which can function at multiple funnel stages. The goal in building a matrix is to ensure you have something that can fit well enough into each space in the matrix to launch a campaign - or if not, to identify and then address any critical gaps. Many ABM programs then refine or add more content over time.

Deploying Content Across ABM Channels

Once content has been selected or created for a campaign, it must be deployed through various channels in order to reach target audiences. Crucially, certain channels tend to work more effectively for certain types of content.

Programmatic advertising can be used to serve TOFU and MOFU content to everyone at target accounts. Targeting is account-level and the purpose is familiarity: the first touches that move unknown contacts toward identified ones. Landing pages, blog posts, and educational guides are the right destinations here, low-friction but valuable enough to earn the click.

LinkedIn advertising enables persona-level delivery. Because LinkedIn targets by title, function, and seniority at specified companies, it is the channel built for running parallel tracks simultaneously: the trial design white paper to clinical program directors and VPs of clinical development, the vendor qualification resource to procurement and operations titles at the same accounts. Each persona sees content calibrated to their role. One budget note: LinkedIn runs expensive per click, so reserve it for key personas and route it to high-value content, not blog posts.

Contact-level advertising goes one step further, serving content to specific named individuals on the buying committee list rather than a title category. It requires a well-constructed contact list, and it returns individually attributable engagement: not "someone in procurement engaged with qualification content," but which person.

Email nurture is the primary MOFU and BOFU vehicle for contacts already in the CRM. A well-built nurture sequence in life science ABM is not a generic drip. It is a sequenced series of messages and additional content aligned to the recipient's role and what they have already engaged with. If the clinical program director at a priority account downloaded a Phase 2 design guide last month, the next email should offer a case study on Phase 2 execution, not an introductory blog post.

Live webinars are among the highest-signal formats available in this market. A webinar on a technically substantive topic (biomarker strategy in oncology, analytical challenges in cell therapy manufacturing) attracts registrants who are actually working on that problem, and every registration produces an identified data point: name, title, company. Attendance, Q&A participation, and post-event downloads add further layers. The strategic value goes beyond the leads. When three people with different titles from the same target account register for one webinar, that is a strong signal, and it should immediately elevate the account and trigger outreach.

Building a Pattern from Signals

Individual engagement events are useful data points, but it's the pattern of engagement across multiple individuals at the same account, across formats, within a defined window that can be indicative of a buying need, and a buying committee.

The pattern to look for is multi-persona, multi-touchpoint engagement concentrated in a short timeframe. A single scientist downloading a white paper is interesting. A clinical program director, a biomarker scientist, and a procurement manager from the same biotech all engaging with MOFU content inside two weeks is a strong signal that something is being evaluated. Layer in a structural signal, such as a new trial registration from that account, and the cumulative case becomes hard to ignore.

When that type of engagement pattern appears, elevate the account. Create a list of the potential buying committee members. (And ideally your systems should be set up to automatically score and elevate the account while creating a report of key target individuals.) Consider contact-level advertising to the key individuals. And have the SDR or BD team open outreach with a contextually informed conversation that references the topics the account has actually been engaging with.

In cases like these, thoughtful and strategic use of content was able to surface a buying committee, identify likely committee members along with their interests, and facilitate a commercial conversation. That is what content as a compass means in practice, and it is the standard a life science ABM content program should be held to.

A Note on Quality

Everything in this post rests on one requirement: the content has to be genuinely good.

Life science buyers are trained evaluators. They'll often know within two pages whether a white paper reflects real expertise or surface familiarity. They will judge within minutes whether a webinar presenter understands the nuances of the problem. Content that fails this test does worse than fail to engage; it damages the credibility it was meant to build.

Producing technically credible, scientifically substantive content is not a trivial investment. It requires deep internal subject-matter expertise, or an external partner who genuinely understands both the science and the commercial context around it. That investment is the prerequisite on which every other element of a content-driven ABM program depends.